Denali Therapeutics Inc logo

DNLI

Denali Therapeutics Inc

$34.89

Earnings Summary

Revenue
$42.14Mn
Net Profits
$-65.22Mn
Net Profit Margins
-154.77%

Highlights

Revenue:

Denali Therapeutics Inc’s revenue jumped 431.88% since last year same period to $42.14Mn in the Q1 2022. On a quarterly growth basis, Denali Therapeutics Inc has generated 236.75% jump in its revenue since last 3-months.

Net Profits:

Denali Therapeutics Inc’s net profit jumped 6.88% since last year same period to $-65.22Mn in the Q1 2022. On a quarterly growth basis, Denali Therapeutics Inc has generated 13.34% jump in its net profits since last 3-months.

Net Profit Margins:

Denali Therapeutics Inc’s net profit margin jumped 82.49% since last year same period to -154.77% in the Q1 2022. On a quarterly growth basis, Denali Therapeutics Inc has generated 74.27% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Denali Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.55
EPS Estimate Current Year
-0.55

Highlights

EPS Estimate Current Quarter:

Denali Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.55 - a -7.84% fall from last quarter’s estimates.

EPS Estimate Current Year:

Denali Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.55.

Key Ratios

Key ratios of the Denali Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.53
Return on Assets (ROA)
-0.13
Return on Equity (ROE)
-0.29
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Denali Therapeutics Inc’s earning per share (EPS) jumped 8.62% since last year same period to -0.53 in the Q1 2022. This indicates that the Denali Therapeutics Inc has generated 8.62% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Denali Therapeutics Inc’s return on assets (ROA) stands at -0.13.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Denali Therapeutics Inc’s return on equity (ROE) stands at -0.29.

Dividend Per Share (DPS):

Denali Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.51
-0.53
-3.92%

Company Information

Denali Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated targets, engineering delivery across the BBB and guiding development through biomarkers that demonstrate target and pathway engagement. Denali is based in South San Francisco.

Organisation
Denali Therapeutics Inc
Headquarters
South San Francisco, California, US
Employees
291
Industry
Health Technology
CEO
Ryan Watts